Physician profile
Kyra S Harvey
NPI 1386745438
$4,604.07
in general payments reported to CMS, 2019-2025
30 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2021: $94.91 · 2022: $712 · 2023: $622 · 2024: $1,076 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.30 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $896.46 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $663.93 | 2019-2025 | Veozah |
| Lilly USA, LLC | $453.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $264.00 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $251.82 | 2019-2025 | Breztri, Airsupra |
| Abbott Laboratories | $218.75 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.75 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $195.29 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $186.26 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $142.49 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.58 | 2022-2025 | Xifaxan |
| Pfizer INC. | $128.95 | 2022-2025 | |
| Dynavax Technologies Corporation | $119.09 | 2022-2025 | Heplisav-B |
| Shield Therapeutics INC | $101.46 | 2023-2025 | Accrufer |
| Abbvie INC. | $98.27 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $96.43 | 2022-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $73.42 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $72.77 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $61.79 | 2019 | |
| Exact Sciences Corporation | $48.93 | 2024-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $37.19 | 2019 | |
| Amgen INC. | $25.06 | 2019 | |
| Biogen, INC. | $22.15 | 2023 | Spinraza |
| Shire North American Group INC | $18.04 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.77 | 2019 | |
| Allergan, INC. | $14.58 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.36 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $14.22 | 2025 | Rexulti |
| Eisai INC. | $13.84 | 2019 | |
| Sanofi Pasteur INC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyra Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.